Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
Rania M. El-Lababidi, Mohamad Mooty, Maria-Fernanda Bonilla, Nouran Salem
Abstract
The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Pneumonia2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)OutbreakCoronavirusVirologyAtypical pneumoniaInternal medicineBetacoronavirusIntensive care medicineDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19